Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 6/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 6/20 | 0.46 |
| ▸ | TAS1R2 | Q8TE23 | 5/20 | 0.46 |
| ▸ | PDE2A | O00408 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SPR | P35270 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5757779 | 0.95 | TAS1R3 (0.53) | ELANETAS1R3TAS1R1TAS1R2ALDH1A1 | |
| SCHEMBL5758228 | 0.83 | RIPK1 (0.51) | PDE10ATAS1R3TAS1R1TAS1R2PDE2A | |
| SCHEMBL5758477 | 0.83 | RIPK1 (0.51) | PDE10ATAS1R3TAS1R1TAS1R2PDE2A | |
| SCHEMBL5758051 | 0.82 | ELANE (0.58) | ELANETAS1R3TAS1R1TAS1R2ALDH1A1 | |
| SCHEMBL5758047 | 0.81 | ELANE (0.56) | ELANEPDE4BPDE4DSMN1; SMN2NOTUM | |
| SCHEMBL5930973 | 0.80 | TAS1R3 (0.50) | PDE10ATAS1R3TAS1R1TAS1R2PDE2A | |
| SCHEMBL5759387 | 0.80 | ELANE (0.53) | ELANEALDH1A1LMNASMN1; SMN2HSD17B10 | |
| SCHEMBL5759586 | 0.79 | ELANE (0.63) | ELANEALDH1A1SMN1; SMN2NOTUM | |
| SCHEMBL5755412 | 0.79 | ELANE (0.54) | ELANESMN1; SMN2NOTUM | |
| SCHEMBL5758365 | 0.78 | ALDH1A1 (0.55) | TAS1R3TAS1R1TAS1R2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562902-B1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | ASRAZENECA AB (SE) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | SERPINB1, ELANE, SERPINE1 | ELANE 2/4885PDE10A 2816/4885TAS1R3 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.